TAILIEUCHUNG - Overview of Trastuzumab’s Utility for Gastric Cancer

Infection with HPV is highly prevalent among gay and bisexual men. This population also has a high incidence of HPV-associated anal lesions and cancer. Gay and bisexual men living with HIV have an even higher inci- dence and progression of disease. This is similar to the story for cervical cancer. However, with strong advocacy and a concerted effort by researchers, clinicians, and public health leaders, dramatic reductions in the incidence of cervical cancer have been achieved. | Trastuzumab Overview of Trastuzumab s Utility for Gastric Cancer Judith Meza-Junco MD Heather-Jane Au MD FRCPC MPH Michael B. Sawyer MD BScPhm FRCPC Department of Oncology Cross Cancer Institute 11560 University Avenue Edmonton Alberta Canada T6G 1Z2 Abstract Gastric Cancer GC is the second leading cause of cancer-related death worldwide and has been managed with different treatment strategies around the world. Surgery is the mainstay of treatment for non-metastatic disease. Because recurrences are common after curative resection adjuvant radio-chemotherapy or perioperative chemotherapy is recommended. The majority of GC patients in clinical practice have advanced or metastatic disease where chemotherapy is considered standard treatment to provide palliation and prolong survival however prognosis remains poor. This paper reviews chemotherapy and targeted therapies for GC focusing on trastuzumab. Key Words Gastric Cancer HER2 Trastuzumab Introduction Gastric cancer GC treatment and prognosis vary in different regions of the world incidence of the disease approach to early diagnosis and treatment varies greatly between western and the eastern hemispheres. It is the second leading cause of cancer-related death worldwide 1 . In the US it was estimated there would be 21 500 new cases and 10 880 deaths from GC in 2008 whereas more than 100 000 new cases are diagnosed and 50 000 die annually of this cancer in Japan. Approximately 50 of GC cases in Japan are diagnosed at an early stage with 5-year survival for stage I GC reported above 90 . In the Western world only 27 of cases are diagnosed at early stage and 5-year survival for stage II-III disease is 20-50 and 5-10 for stage IV. Different strategies have been tested around the world and have resulted in different approaches for localized and advanced GC as summarized in Figure 1. Chemotherapy for GC Locoregional and distant recurrences are frequently seen after surgery for GC therefore different approaches as adjuvant .

• Y học thường thức
• Mechanisms contributing
• patient knowledge
• understanding and concerns
• quality assured generic
• medicines and promoting
• appropriate actions
• BMC Genomics
• Deep diving
• Marine mammals
• Gene regulation
• Leptonychotes weddelli
• Extreme cardiovascular control
• Drought Environments
• Response Crosstalk
• Reactive Oxygen
• specific difficulties